Kurzfassung

A phase 1/2, first-in-human, dose escalation study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) bi-specific antibody-based molecule, in patients with relapsed or refractory acute myeloid leukemia or intermediate-2/high risk myelodysplastic syndrome - MGD006